Pfizer’s purpose is to develop breakthroughs that change people’s lives. In the face of COVID-19, this call is more urgent than ever, and we have aimed to leave no stone unturned as we have harnessed the full breadth and depth of our resources to address this crisis.
During COVID-19 Pfizer’s actions have been guided by three priorities:
First, ensuring the safety and well-being of our colleagues;
Second, ensuring the continued supply of our medicines and vaccines to patients who need them across the world
Research & Development
Third, continuing our commitment to collaborate and play our part in discovering breakthrough therapies and vaccines to put an end to this pandemic.
In response to the pandemic, globally Pfizer has created a SWAT team of our leading virologists, biologists, chemists, clinicians, epidemiologists, vaccine experts, pharmaceutical scientists and other key experts to focus solely on the discovery of an effective vaccine and/or a treatment to put an end to this pandemic.
Pfizer is committed to bringing this candidate vaccine to help meet the global public health need on an equitable basis. We are working closely with international initiatives, governments, and other stakeholders, as appropriate, to supply the world as quickly as we can, together. Alongside leading biopharmaceutical companies who are also conducting vaccine research and development, we’ve announced a historic pledge that outlines a united commitment to uphold the integrity of the scientific process as we work towards developing a potential vaccine for COVID-19 that puts patient safety and public health as top priorities.
At a local level our aim has been to provide critical support to the healthcare practitioners at the frontline of this pandemic, the communities in which we operate and the patients whom we ultimately serve. To this effect, Pfizer has made a contribution of $500,000 to the Solidarity Fund; provided over R1 million to NGOs providing food and other essential items to vulnerable communities; and has donated more than R500,000 towards Covid-19 HCP education and the development of education and navigation materials for high-risk patient groups who are at greater risk of death should they contract the virus.
On 30 September we announced the start of enrollment in South Africa for the Phase 3 pivotal COVID-19 vaccine trial. We are proud to have brought this important study to the country - and to the African Continent - to add to the growing knowledge of this virus in the endeavor to find a lasting and sustainable solution to end this pandemic.
With the global collaboration and unprecedented commitment to ending this pandemic we are confident that #sciencewillwin.